FDA warned Eco Lips, Inc. that its over-the-counter sunscreen drug products had serious manufacturing and testing failures.
What happened
FDA inspected Eco Lips, Inc.'s drug manufacturing facility in Cedar Rapids, Iowa, from March 22 to March 24, 2022. The inspection found inadequate stability testing and expiration dates, failed test results that were not investigated before batches were released, missing process validation for most sunscreen groups, inadequate cleaning validation, and incomplete annual product reviews. FDA said these were repeat violations from 2019 and 2021 inspections and that manufacturing did not meet Current Good Manufacturing Practice (CGMP), the FDA's drug manufacturing rules.
What FDA found
Eco Lips did not have an adequate stability program or data to support expiration dates for its over-the-counter drug products.
21 CFR 211.166(a)Eco Lips did not thoroughly investigate batches that failed tests and released some batches even after test results failed.
21 CFR 211.192Eco Lips had not validated the manufacturing processes for seven of nine over-the-counter sunscreen product groups.
21 CFR 211.100(a)Eco Lips did not validate cleaning of shared equipment, did not test for cleaning-agent residue removal, and lacked data on how long cleaning samples could be held.
21 CFR 211.67(b)Eco Lips did not complete annual product reviews for all its drug products.
21 CFR 211.180(e)
What FDA wants
FDA tells Eco Lips to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence, including the requested assessments and plans. If it cannot complete corrective actions in that time, it must explain the delay and give a completion schedule.
Who should pay attention
- brands that buy over-the-counter drug products from Eco Lips as a contract manufacturer
- retailers and distributors selling Eco Lips sunscreen drug products
- quality teams overseeing contract manufacturers of over-the-counter drugs
This is a summary. Read the original letter on fda.gov.